MDGL Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -259.95%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Insmed, Inc.'s return on equity of -193.23%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $671.07, signalling upside risk potential of 44.41%. On the other hand Insmed, Inc. has an analysts' consensus of $214.37 which suggests that it could grow by 44.11%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Insmed, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.010, which suggesting that the stock is 201.017% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is higher than Insmed, Inc.'s net income of -$370M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.92x versus 63.30x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -82.06%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $671.07, signalling upside risk potential of 44.41%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 13.06%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.010, which suggesting that the stock is 201.017% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.92x versus 13.72x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 34.4%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Eli Lilly & Co.'s return on equity of 104.39%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $671.07, signalling upside risk potential of 44.41%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.54%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Madrigal Pharmaceuticals, Inc. has a beta of -1.010, which suggesting that the stock is 201.017% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.73 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.92x versus 14.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -9.34%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Pfizer Inc.'s return on equity of 10.84%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $671.07, signalling upside risk potential of 44.41%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 3.8%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.010, which suggesting that the stock is 201.017% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.24% to investors and pays a quarterly dividend of $0.43 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.92x versus 2.51x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.